PREEXISTING COMORBIDITIES PREDICTING SEVERE COVID-19 IN OLDER ADULTS IN THE UK BIOBANK COMMUNITY COHORT

Janice L Atkins, PhD¹, Jane AH Masoli, MBChB^{1,2}, Joao Delgado, PhD¹, Luke C Pilling, PhD^{1,3}, Chia-Ling Kuo, PhD³, George A Kuchel MD³, David Melzer MBBCh PhD^{11,3}

¹ Epidemiology and Public Health Group, University of Exeter Medical School, Exeter, UK ²Department of Healthcare for Older People, Royal Devon and Exeter Hospital, Barrack Road, Exeter, UK.

³Center on Aging, University of Connecticut Health Center, Farmington, CT, USA

Corresponding author: Professor David Melzer. Epidemiology and Public Health Group, University of Exeter Medical School, College House, St. Luke's Campus, Exeter, EX1 2LU, UK. Email: <u>D.Melzer@exeter.ac.uk</u>

Manuscript word count: 2832

Running title: Comorbidities predicting severe COVID-19 in older adults in UK Biobank

Key words: COVID-19; Morbidity; Epidemiology

Abstract

Background: Older COVID-19 hospitalized patients frequently have hypertension, diabetes or coronary heart disease (CHD), but whether these are more common than in the population is unclear. During the initial epidemic in England, virus testing for older adults was restricted to symptomatic hospitalized patients. We aimed to estimate associations between pre-existing diagnoses and COVID-19 status, in a large community cohort.

Methods: UK Biobank (England) participants assessed 2006 to 2010, followed in hospital discharge records to 2017. Demographic and pre-existing common diagnoses association tested with COVID-19 status (16th March to 14th April 2020) in logistic models, adjusted for demographics, study site and other diagnoses.

Results: There were 274,356 participants aged 65+, including 448 (0.16%) hospitalized COVID-19 patients. Common co-morbidities in patients were hypertension (58.5%), coronary heart disease (CHD, 21.1%), history of fall or fragility fractures (30.6%), and type 2 diabetes (19.6%). However, in adjusted models, COVID-19 patients were more likely than other participants to have pre-existing dementia (OR=3.07 95% CI 1.71 to 5.50), COPD (OR= 1.82 CI 1.33 to 2.49), depression (OR=1.81 CI 1.36 to 2.40), type 2 diabetes (OR=1.70 CI 1.30 to 2.21), chronic kidney disease and atrial fibrillation. Hypertension was modestly associated (OR=1.29 CI 1.04 to 1.59), but CHD (OR=0.92 CI 0.71 to 1.20) prevalence was similar in COVID-19 patients and other participants.

Conclusion: Specific co-morbidities are disproportionally common in older adults who develop severe COVID-19. Tailored interventions may be needed, as these results do not support simple age-based targeting to prevent severe COVID-19 infection.

Introduction

The 2019 novel coronavirus (SARS-COV-19) has caused a global pandemic [1], with a wide spectrum of clinical disease presentations, from asymptomatic infection to respiratory failure with high mortality [2]. However, little is known about what predicts COVID-19 severity in different individuals.

The majority of patients hospitalized with COVID-19 are older and have underlying medical conditions [3,4]. Analyses of COVID-19 patients have reported that increased age is associated with clinical severity [5,6], including case fatality [4,7]. The most frequent co-morbidities in Chinese cohorts of COVID-19 patients were hypertension (21.1%, 95% CI: 13.0–27.2%) and diabetes (9.7%, 95% CI: 7.2–12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8–13.8%) and respiratory system disease (1.5%, 95% CI: 0.9– 2.1%) [8] and in a large US cohort: hypertension (56.6%), obesity (41.7%), and diabetes (33.8%) [6]. However, co-morbidities vary with patient age-group, and in those aged over 70, obesity is less common and dementia is more common [3]. Such data on common co-morbidities in hospitalized patients is important for understanding the acute treatment challenge, but it is unclear whether these conditions are common in COVID-19 patients merely because they are also common in the older population. To identify those at most risk of severe COVID-19, data are needed on which pre-existing conditions are disproportionately common in severely affected patients compared to the background population.

The United Kingdom Biobank (UKB) is a community-based cohort of 500,000 participants currently aged 48 to 86 [9]. UKB recently added linkage to National Health Service COVID-19 laboratory test results in England for the period March 16 to April 14 2020, thus including the peak period of daily COVID-19 laboratory-confirmed cases in the current outbreak [10]. During this period, testing of older groups was essentially restricted to hospital in-patients

with clinical signs of infection [11], so test positivity is a good marker of severe COVID-19 [12]. Given the scarcity of cohort data on risk factors for severe COVID in older groups, we undertook an initial analysis of baseline (2006 to 2010) demographic characteristics and preexisting diagnoses during UK Biobank (UKB) follow-up. Identifying the specific risk factors explaining why some older people are severely affected by COVID-19 than others may give clues to underlying vulnerabilities, and are critical to developing outbreak control policies that focus on individual risk and avoid imposing crude age based public health controls [13].

Methods

UK Biobank Cohort

The UK Biobank consists of over 500,000 community volunteers aged 40 to 70 year at baseline (2006 to 2010), living close to 22 assessment centers in England, Scotland and Wales [9]. Baseline assessments included demographics, lifestyle and disease history, with linkages to electronic medical records. UK Biobank ethical approval was from the North West Multi-Centre Research Ethics Committee. The current analysis was approved under UKB application 14631 (PI Melzer, D).

COVID-19 test status and sample selection

Of 1,474 UK Biobank participants of all ages with available data, 669 were laboratoryconfirmed active COVID-19 infection (by PCR) from test preformed between March 16 and April 14, 2020, in England only. During this period, COVID-19 testing was restricted to hospitalized patients with clinical signs of the disease, plus health care workers [14,15]. We restricted analyses to participants aged 65 years and older when tested (or age on April 14 if not tested), to minimize misclassification of disease severity from health care workers (who

were tested even for mild possible infections): this included 448 older study participants testing COVID-19 positive. We also excluded participants previously reported to have died during UK Biobank follow-up (n=20,348, death registration records available until January 2018). No COVID-19 test data were available for UKB assessment centers in Scotland and Wales, so data from these centers were not included.

Disease ascertainment

Preexisting diagnoses were available from baseline questionnaires (2006-10) eliciting participant reports of doctor diagnosed disease. New disease diagnoses since baseline were from linked electronic medical records to hospital inpatient routine data (to March 2017), coded according to the International Classification of Diseases 10th revision (ICD-10). Diagnoses included were coronary heart disease (CHD), atrial fibrillation, stroke, hypertension, diabetes (type 2), chronic kidney disease (CKD, stages 3 to 5), depression, dementia, asthma, chronic obstructive pulmonary disease (COPD), osteoporosis and osteoarthritis. We also identified previous diagnoses of delirium, pneumonia and falls or fragility fractures (See definitions in Supplementary Table 1). We combined each diagnosis reported at baseline or from linked hospital data to generate pre-existing diagnosis status for each participant.

Statistical Analysis

We estimated associations of demographic and diagnoses with COVID-19 test positivity using logistic regression models, with 95% confidence intervals. Logistic models were adjusted for age group (in five year age bands), sex, ethnicity, education and assessment center at baseline (to account for geographic differences in the prevalence of COVID-19

infection). A p-value smaller than 5% was considered statistically significant. All the statistical analyses were performed in Stata version 15.1.

Results

There were 274,356 older adults (aged 65 to 86 years, mean 73.2 years) eligible for the analysis, of whom 448 (0.16%) were laboratory test positive COVID-19 patients, with rates of infection varying widely across UK Biobank baseline assessment centers (0.38% to 0.07%, see Supplementary Table 2). The mean age of patients (Table 1) was 74.3 years (SD 4.5) in COVID-19 test positive patients and 73.2 years (SD 4.4) for other study participants. Both patients and others were predominantly of 'white' ethnicity, but people self-reporting 'Black' ethnicity made up 5.2% of patients but only 1% of participants. The most common diagnoses in cases were hypertension (58.5%), a history of falls or fragility fractures (30.6%), CHD (21.1%), diabetes (type 2, 19.6%), asthma (18.2%). Dementia was present in 3.4% of patients (0.5% of other participants). COVID-19 patients had a mean of 2.4 diagnoses (of a possible 15 diagnoses examined) compared to other participants with 1.4 diagnoses.

In logistic modelling of demographic variables (Table 2, 'demographics', also accounting for assessment center), risks in those aged 80+ years were markedly raised (Odds Ratio OR=2.24 95% CI 1.53 to 3.30, p=4.10E-05) compared to age-group 65 to 69, with no risk increase in 70 to 74 years old and intermediate risks in 75 to 80 years old. Males were substantially more likely to be COVID-19 test positive patients (OR=1.89 CI 1.56 to 2.30, p=1.60E-10) and people of Black ethnicity were at higher risk (OR 4.05, CI 2.55 to 6.43, p=2.90E-09) compared to White, with South Asians and other ethnicities having intermediate risks. Compared to those with degree level education, having no education qualifications (OR 2.10 CI 1.61 to 2.74, p=4.60E-08) was associated with raised risks of COVID-19. All studied

diagnoses individually (adjusted for demographics only) were associated with COVID-19 (Supplementary Table 3). As different chronic diseases often co-exist together in older adults, we estimated risks for each diagnosis accounting for other diagnoses present. In fully adjusted models (Table 2, Full model), the excess risk in men was virtually unchanged by adjustment for diagnoses (OR 1.83 (1.49 to 2.25, p=7.00E-09), but there were somewhat lower risks in the 80+ year olds (OR 1.76 CI 1.19 to 2.62, p=5.00E-03, compared to 65 to 69). Also, dementia emerged as being associated with the largest increase in risks of COVID-19 (OR=3.07 CI 1.71 to 5.50, p=1.60E-04) followed by COPD (OR 1.82 CI 1.33 to 2.49, p=1.90E-04), depression (OR 1.81 CI 1.36 to 2.4, p=3.90E-05), diabetes (OR=1.7 CI 1.3 to 2.21, p=8.90E-05), chronic kidney disease (OR 1.60 CI 1.03 to 2.49, p=3.80E-02) and atrial fibrillation (OR 1.51 CI 1.12 to 2.05, p=7.70E-03), with a relatively modest risk increase with hypertension (OR= 1.29 CI 1.04 to 1.59, p=2.00E-02). Coronary heart disease (CHD) prevalence, previously noted as common in COVID-19 patients, did not differ between patients and other participants (OR=0.92 CI 0.71 to 1.20, p=5.30E-01) in the models adjusted for demographics and other diagnoses. In sex specific analyses (Table 3) of COVID-19, there were associations in women for dementia (OR=5.22 CI 2.21 to 12.31, p=1.60E-04), depression, chronic kidney disease, asthma and COPD, and in men, dementia, depression, atrial fibrillation and diabetes reached statistical significance: however, the confidence intervals overlapped for the diagnoses that differed by sex.

Discussion

We aimed to identify risk factors associated with COVID-19 test positivity in older hospital inpatients during the peak of the initial epidemic in England. We found that some chronic conditions reported as common co-morbidities in COVID-19 patients (and postulated as major risk factors), were modestly (diabetes, hypertension) or not (CHD) significantly more common with COVID-19 than in other older UK Biobank participants. Instead, pre-existing

diagnoses of dementia, COPD, depression, chronic kidney disease and atrial fibrillation emerged as independent risk factors. In keeping with other studies, we also found increased risk of COVID-19 in males, but we have shown that this risk is virtually unchanged after adjusting for co-morbidities. In addition, we confirmed previous reports that people of Black ethnicity, and those with no educational qualifications had higher risk. Overall, these results suggest that there are specific risk co-morbidities in older groups, and that severe COVID-19 susceptibility is not merely the result of advancing age.

Hypertension is well-recognized as the most common chronic diagnosis, prevalent in over 70% of persons at ages over 80 [16]. While highly prevalent in the UKB cohort, we found that it was only modestly more common in COVID-19 cases than in other UKB participants. Interestingly, we found that having a diagnosis of CKD (grade 3 to 5) was associated with being COVID-19 positive, mirroring previous analyses by Masoli et al [17], who found that CKD grade is more predictive of mortality than blood pressure in adults age over 70. CKD has also been reported to be associated with increased hospitalisation with infection, particularly pneumonia, and increased 30 day mortality [18,19].

Another novel finding is the association between atrial fibrillation and hospitalized COVID-19 in the studied older adults. During atrial fibrillation, the loss of atrio-ventricular synchrony with decreased diastolic filling time is likely to lead to a decrease in cardiac output. Consequently, this low cardiac output may aggravate tissue hypoxia in COVID-19 patients. Also, agents used in the control of atrial fibrillation, particularly sotalol, propafenone, and non-selective β -blockers, may cause bronchospasm [20]. Pulmonary symptoms in COPD may become worse with atrial fibrillation development, due to excessive irregular heart rate, as well as reduced diastolic filling of the ventricles [21]. These factors may contribute to higher severe COVID-19 risk in participants with atrial fibrillation. The relationship between diabetes and COVID-19 has been widely noted, with diabetes associated with increased severity [22]. However, the association between diabetes and clinical severity of COVID-19 in diabetes reduced at older ages, compared to under 55 year olds [23], and we found a relatively modest association between diabetes and COVID-19 in our study. Unfortunately, the UK Biobank data lacks a recent measure of adiposity, but the effects of obesity are likely evident in the raised risks with diabetes and other related conditions.

To date there has been very limited data on dementia and COVID-19, despite dementia affecting over 50 million people worldwide [24]. This may be due to the young median ages of many published COVID-19 case series, with limited characterisation of older persons. Our analysis has revealed dementia to be the largest effect risk diagnosis in adults aged over 65, in this cohort of community volunteers. A recent report of observational data from the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) found a high prevalence of dementia in older adults admitted to hospital with COVID-19 [3]. Future work will need to clarify the mechanisms involved and aim to establish whether this a direct effect of dementia pathologies, or an indirect effect of high rates of infection in nursing homes.

UK Biobank participants were somewhat healthier than the general population [25] at baseline in 2006 to 2010, but the sample nevertheless includes large numbers of socioeconomically less privileged participants: for example, 36.1% of cases and 22.3% of controls had no educational qualifications (Table 1). Other limitations include the lack of details of the hospitalization and degrees of clinical severity within cases, although at the peak of the epidemic, access to intensive care units for older patients may partly reflect resource scarcity rather than severity of illness. Only a small proportion of the English population has thus far been exposed to the virus, but the group studied here were exposed and developed severe enough COVID-19 to be tested during hospitalization. Our case group is therefore relevant for assessing risk factors for severe COVID-19 in this older population. Our diagnostic data is derived from participant's baseline interviews plus hospital discharge data until March 2017, so under-ascertainment of disease is likely, especially for recently diagnosed conditions, but the similarity to previous reports of the common conditions seen in COVID-19 patients suggests that our data are valid.

Our results should have implications for preventive interventions, encouraging a more targeted approach prioritizing those older adults with specific risk factors, rather than adopting policies that use chronological age as a blanket indicator of risk. Our cohort evidence of specific risk factors may also help with avoiding potentially 'ageist' approaches to setting clinical priorities in over-stretched health systems [26]. Our findings of risks associated with less prominent conditions such as atrial fibrillation and CKD could help focus clinical research, as patients these conditions may need specific interventions to reduce risks of COVID-19 severity. In addition, the prominence of depression as one of the major risk factors highlights the role of mental health [27] as critical to managing the pandemic, including in older people.

Conclusion

In older adults, several specific pre-existing co-morbidities are disproportionally common in severe COVID-19 patients, notably including dementia, depression, atrial fibrillation and chronic kidney disease. Clinical and public health research is needed to establish the mechanisms involved and whether stratified interventions are needed for older patients with specific comorbidities. A history of coronary heart disease is common in both COVID-19 hospitalized patients and other study participants. Our results do not support simple age targeting of interventions to prevent severe COVID-19 infection.

Conflict of interest disclosures: None reported.

Acknowledgements: This research was conducted using the UK Biobank resource, under application 14631. We thank the UK Biobank participants and coordinators for the dataset.

Author contributions: JLA & DM performed the statistical analysis of data. DM, JAHM, JD and JLA drafted the manuscript. All authors were involved in design of the study, interpretation of data and revision of the manuscript.

Funding: UK Medical Research Council award MR/S009892/1 (PI Melzer) supports JLA. DM and LCP are supported by the University of Exeter Medical School, and in part by the University of Connecticut School of Medicine. JAHM is supported by NIHR Doctoral Research Fellowship DRF-2014-07-177. Input from CLK was supported by the University of Connecticut. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.

	COVID-19 positive test			No COVID-19 positive test		
	Men	Women	Total	Men	Women	Total
Total number	275	173	448	124,430	149,478	273,908
Age, mean (SD)	74.63 (4.40)	73.77 (4.62)	74.30 (4.50)	73.32 (4.38)	73.02 (4.35)	73.16 (4.37)
Age 65-69	46 (16.7)	42 (24.3)	88 (19.6)	32,115 (25.8)	41,728 (27.9)	73,843 (27.0)
Age 70-74	85 (30.9)	58 (33.5)	143 (31.9)	45,364 (36.5)	56,350 (37.7)	101,714 (37.1)
Age 75-79	119 (43.27)	57 (33.0)	176 (39.3)	39,112 (31.4)	43,013 (28.8)	82,125 (30.0)
Age 80+	25 (9.1)	16 (9.3)	41 (9.2)	7,839 (6.3)	8,387 (5.6)	16,226 (5.92)
Ethnicity						
White	246 (90.8)	148 (86.1)	394 (88.9)	118,937 (96.2)	143,100 (96.2)	262,037 (96.2)
Black	12 (4.4)	11 (6.4)	23 (5.2)	1,129 (0.9)	1,640 (1.1)	2,769 (1.0)
South Asian	6 (2.2)	8 (4.7)	14 (3.2)	2,249 (1.8)	2,014 (1.35)	4,263 (1.6)
Other (incl. mixed & Chinese)	7 (2.6)	5 (2.9)	12 (2.7)	1,302 (1.1)	2,073 (1.4)	3,375 (1.2)
Education						
None	98 (37.7)	56 (33.5)	154 (36.1)	26,134 (21.5)	33,582 (23.0)	59,716 (22.3)
School/College	64 (24.6)	45 (27.0)	109 (25.5)	38,125 (31.3)	48,985 (33.5)	87,110 (32.5
Professional qualification	41 (15.8)	28 (16.8)	69 (16.2)	18,201 (15.0)	24,293 (16.6)	42,494 (15.9)
Degree	57 (21.9)	38 (22.8)	95 (22.3)	39,236 (32.2)	39,340 (26.9)	78,576 (29.3)
Prevalent disease*						
CHD	70 (25.5)	25 (14.5)	95 (21.1)	21,099 (17.0)	11,374 (7.6)	32,473 (11.9)
Atrial fibrillation	46 (16.7)	11 (6.3)	57 (12.7)	9,865 (7.9)	5,354 (3.6)	15,219 (5.6)
Stroke	15 (5.5)	7 (4.1)	22 (4.9)	3,443 (2.8)	2,379 (1.6)	5,822 (2.1)
Hypertension	169 (61.5)	93 (53.8)	262 (58.5)	58,002 (46.6)	55,236 (37.0)	11,3238 (41.3)
Diabetes (type 2)	61 (22.2)	27 (15.6)	88 (19.6)	11,713 (9.4)	7,868 (5.3)	19,581 (7.2)
Chronic kidney disease	12 (4.4)	11 (6.4)	23 (5.1)	2,057 (1.7)	2,191 (1.5)	4,248 (1.6)
Depression	35 (12.7)	30 (17.3)	65 (14.5)	7,078 (5.7)	13,080 (8.8)	20,158 (7.4)
Dementia	9 (3.3)	6 (3.5)	15 (3.4)	620 (0.5)	628 (0.4)	1,248 (0.5)
Asthma	37 (13.5)	45 (26.0)	82 (18.2)	14,623 (11.8)	20,929 (14.0)	35,552 (13.0)
COPD	33 (12.0)	27 (15.6)	60 (13.4)	6,409 (5.2)	6,047 (4.1)	12,456 (4.6)
Osteoporosis	8 (2.9)	14 (8.1)	22 (4.9)	1,272 (1.0)	6,600 (4.4)	7,872 (2.9)
Osteoarthritis	39 (14.2)	41 (23.7)	80 (17.9)	13,518 (10.9)	24,057 (16.1)	37,575 (13.7)
Previous disease/condition*						
Delirium	6 (1.3)	0	6 (1.3)	432 (0.4)	347 (0.2)	779 (0.3)
Pneumonia	31 (11.3)	13 (7.5)	44 (9.8)	5,766 (4.6)	5,391 (3.6)	11,157 (4.1)
Falls/Fragility fractures	71 (25.8)	66 (38.2)	137 (30.6)	23,536 (18.9)	45,145 (30.2)	68,681 (25.1)
Number of above diseases (max 15), mean (SD)	2.3 (1.9)	2.4 (1.8)	2.4 (1.8)	1.4 (1.4)	1.4 (1.4)	1.4 (1.4)
Number of hospital admissions, mean (SD)	5.9 (10.8)	5.0 (6.6)	5.6 (9.4)	3.1 (10.4)	2.8 (6.7)	2.9 (8.6)

Table 1. Descriptive characteristics of UK Biobank cohort by COVID-19 test positivity

Numbers presented are n (%) unless otherwise specified

*Diagnoses from baseline self-report and hospital inpatient admissions

	Demographics		Full model		
	OR (95% CI)	p-value	OR (95% CI)	p-value	
Age					
Age 65-69					
Age 70-74	1.16 (0.88 to 1.53)	2.90E-01	1.11 (0.84 to 1.46)	4.80E-01	
Age 75-79	1.65 (1.26 to 2.16)	2.60E-04	1.44 (1.09 to 1.89)	9.20E-03	
Age 80+	2.24 (1.53 to 3.30)	4.10E-05	1.76 (1.19 to 2.62)	5.00E-03	
Sex					
Female					
Male	1.89 (1.56 to 2.30)	1.60E-10	1.83 (1.49 to 2.25)	7.00E-09	
Ethnicity					
White					
Black	4.05 (2.55 to 6.43)	2.90E-09	3.69 (2.31 to 5.89)	4.60E-08	
South Asian	1.82 (1.03 to 3.22)	3.90E-02	1.54 (0.87 to 2.75)	1.40E-01	
Other (inc. mixed & Chinese)	1.98 (1.05 to 3.75)	3.60E-02	1.81 (0.95 to 3.44)	6.90E-02	
Education					
Degree					
Professional qualification	1.42 (1.04 to 1.95)	2.80E-02	1.33 (0.97 to 1.83)	7.40E-02	
School/College	1.12 (0.85 to 1.48)	4.30E-01	1.04 (0.78 to 1.37)	8.10E-01	
None	2.10 (1.61 to 2.74)	4.60E-08	1.71 (1.30 to 2.24)	1.10E-04	
Prevalent disease*					
Coronary heart disease			0.92 (0.71 to 1.20)	5.30E-01	
Atrial fibrillation			1.51 (1.12 to 2.05)	7.70E-03	
Stroke			1.25 (0.79 to 1.96)	3.40E-01	
Hypertension			1.29 (1.04 to 1.59)	2.00E-02	
Diabetes (type 2)			1.70 (1.3 to 2.21)	8.90E-05	
Chronic kidney disease			1.60 (1.03 to 2.49)	3.80E-02	
Depression			1.81 (1.36 to 2.4)	3.90E-05	
Dementia			3.07 (1.71 to 5.5)	1.60E-04	
Asthma			1.13 (0.87 to 1.47)	3.60E-01	
COPD			1.82 (1.33 to 2.49)	1.90E-04	
Osteoporosis			1.42 (0.91 to 2.23)	1.20E-01	
Osteoarthritis			1.10 (0.85 to 1.42)	4.90E-01	
Previous disease/condition*					
Delirium			1.22 (0.51 to 2.90)	6.60E-01	
Pneumonia			1.40 (0.99 to 1.97)	5.50E-02	
Falls/Fragility fractures			1.15 (0.92 to 1.42)	2.10E-01	

Table 2. Odds ratios for associations between A) demographic variables and COVID-19 status, and B) pre-existing diagnoses and COVID-19, accounting for demographics plus other diagnoses (full adjustment model)

*Diagnoses from baseline self-report and hospital inpatient admissions

Demographics model (adjusted for age group, sex, ethnicity, education, and baseline assessment centre)

Full model (adjusted for age group, sex, ethnicity, education, assessment centre and all the above diseases/conditions)

Table 3. Odds ratios for associations between pre-existing diagnoses and COVID-19 status, accounting for demographics plus other diagnoses (full adjustment model), stratified by sex

	WOMEN		MEN Full adjustment		
	Full adjustme	ent			
	OR (95% CI)	p-value	OR (95% CI)	p-value	
Prevalent disease*					
Coronary heart disease	0.82 (0.50 to 1.36)	4.50E-01	0.96 (0.70 to 1.31)	7.90E-01	
Atrial fibrillation	1.06 (0.54 to 2.07)	8.70E-01	1.71 (1.21 to 2.41)	2.40E-03	
Stroke	1.29 (0.56 to 3.00)	5.50E-01	1.22 (0.71 to 2.10)	4.60E-01	
Hypertension	1.36 (0.98 to 1.9)	7.00E-02	1.24 (0.94 to 1.63)	1.30E-01	
Diabetes (type 2)	1.6 (1.00 to 2.55)	5.00E-02	1.76 (1.27 to 2.42)	5.80E-04	
Chronic kidney disease	2.29 (1.19 to 4.38)	1.30E-02	1.24 (0.67 to 2.28)	4.90E-01	
Depression	1.69 (1.11 to 2.58)	1.40E-02	1.90 (1.30 to 2.78)	9.60E-04	
Dementia	5.22 (2.21 to 12.31)	1.60E-04	2.33 (1.07 to 5.05)	3.20E-02	
Asthma	1.47 (1.01 to 2.14)	4.40E-02	0.90 (0.62 to 1.31)	5.80E-01	
COPD	2.59 (1.60 to 4.18)	1.00E-04	1.49 (0.98 to 2.25)	6.00E-02	
Osteoporosis	1.21 (0.68 to 2.15)	5.20E-01	1.90 (0.92 to 3.91)	8.30E-02	
Osteoarthritis	1.17 (0.81 to 1.70)	4.10E-01	1.01 (0.70 to 1.44)	9.80E-01	
Previous disease/condition*					
Delirium	No observations		2.08 (0.86 to 5.04)	1.10E-01	
Pneumonia	1.25 (0.68 to 2.30)	4.60E-01	1.48 (0.98 to 2.26)	6.50E-02	
Falls/Fragility fractures	1.15 (0.84 to 1.59)	3.90E-01	1.14 (0.86 to 1.52)	3.70E-01	

*Diagnoses from baseline self-report and hospital inpatient admissions

Full model (adjusted for age group, ethnicity, education, assessment centre and all the above diseases/conditions).

References

- Jin H, Hong C, Chen S, *et al.* Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. *Stroke Vasc Neurol* 2020;:svn-2020-000382. doi:10.1136/svn-2020-000382
- 2 Cascella M, Rajnik M, Cuomo A, *et al.* Features, Evaluation and Treatment Coronavirus (COVID-19). 2020.
- International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC). COVID-19 Report: 20 April 2020. 2020.
- Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients
 Dying in Relation to COVID-19 in Italy. *JAMA* Published Online First: March 2020.
 doi:10.1001/jama.2020.4683
- 5 Guan W, Ni Z, Hu Y, *et al.* Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020;:NEJMoa2002032. doi:10.1056/nejmoa2002032
- Richardson S, Hirsch JS, Narasimhan M, *et al.* Presenting Characteristics,
 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in
 the New York City Area. *JAMA* Published Online First: April 2020.
 doi:10.1001/jama.2020.6775
- Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* (*London, England*) 2020;**395**:1054–62. doi:10.1016/S0140-6736(20)30566-3
- ⁸ J Y, Y Z, X G, *et al.* Prevalence of Comorbidities and Its Effects in Coronavirus Disease 2019 Patients: A Systematic Review and Meta-Analysis. *Int J Infect Dis*

2020;**94**. doi:10.1016/J.IJID.2020.03.017

- 9 Sudlow C, Gallacher J, Allen N, *et al.* UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. *PLoS Med* 2015;**12**:e1001779. doi:10.1371/journal.pmed.1001779
- GOV.UK. Coronavirus (COVID-19) in the UK.
 https://coronavirus.data.gov.uk/?_ga=2.149906868.326071066.1587984690 2080271140.1587984690 (accessed 27 Apr 2020).
- Iacobucci G. Covid-19: What is the UK's testing strategy? *BMJ* 2020;**368**:m1222.doi:10.1136/bmj.m1222
- 12 GOV.UK. Coronavirus (COVID-19): Using data to track the virus. https://publichealthmatters.blog.gov.uk/2020/04/23/coronavirus-covid-19-using-datato-track-the-virus/ (accessed 27 Apr 2020).
- Armitage R, Nellums LB. COVID-19 and the consequences of isolating the elderly.*Lancet Public Heal*;0. doi:10.1016/S2468-2667(20)30061-X
- 14 NHS. Coronavirus guidance for clinicians and clinical managers.
- 15 gov.uk. Coronavirus (COVID-19): Using data to track the virus Public health matters.
- 16 Lloyd-Jones DM, Evans JC, Levy D. Hypertension in Adults Across the Age Spectrum. JAMA 2005;294:466. doi:10.1001/jama.294.4.466
- Masoli JAH, Delgado J, Bowman K, *et al.* Association of blood pressure with clinical outcomes in older adults with chronic kidney disease. *Age Ageing* 2019;48:380–7.
 doi:10.1093/ageing/afz006

- Ishigami J, Grams ME, Chang AR, *et al.* CKD and Risk for Hospitalization With Infection: The Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis* 2017;69:752. doi:10.1053/J.AJKD.2016.09.018
- James MT, Quan H, Tonelli M, *et al.* CKD and Risk of Hospitalization and Death
 With Pneumonia. *Am J Kidney Dis* 2009;54:24–32. doi:10.1053/J.AJKD.2009.04.005
- 20 International Consortium for Blood Pressure Genome-Wide Association Studies TIC for BPG-WA, Ehret GB, Munroe PB, *et al.* Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature* 2011;478:103–9. doi:10.1038/nature10405
- Ferreira C, Providência R, Ferreira MJ, *et al.* Atrial Fibrillation and Non-cardiovascular Diseases: A Systematic Review. *Arq Bras Cardiol* 2015;105:519–26. doi:10.5935/abc.20150142
- Guo W, Li M, Dong Y, *et al.* Diabetes is a risk factor for the progression and prognosis of COVID-19. *Diabetes Metab Res Rev* 2020;:e3319.
 doi:10.1002/dmrr.3319
- Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, metaanalysis, and meta-regression. *Diabetes Metab Syndr* 2020;**14**:395–403. doi:10.1016/J.DSX.2020.04.018
- Wang H, Li T, Barbarino P, *et al.* Dementia care during COVID-19. *Lancet* 2020;395:1190–1. doi:10.1016/S0140-6736(20)30755-8
- 25 Fry A, Littlejohns TJ, Sudlow C, *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General

Population. Am J Epidemiol 2017;186:1026-34. doi:10.1093/aje/kwx246

- Boreskie KF, Boreskie PE, Melady D. Age is just a number and so is frailty□:
 Strategies to inform resource allocation during the COVID-19 pandemic. *CJEM*2020;:1–3. doi:10.1017/cem.2020.358
- Holmes EA, O'Connor RC, Perry VH, *et al.* Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. *The Lancet Psychiatry* Published Online First: April 2020. doi:10.1016/s2215-0366(20)30168-1